139 related articles for article (PubMed ID: 24272204)
1. The prognostic value of Smad4 mRNA in patients with prostate cancer.
Zhang DT; Shi JG; Liu Y; Jiang HM
Tumour Biol; 2014 Apr; 35(4):3333-7. PubMed ID: 24272204
[TBL] [Abstract][Full Text] [Related]
2. Association of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 with the prognosis of esophageal squamous cell carcinoma.
Lv J; Cao XF; Ji L; Zhu B; Wang DD; Tao L; Li SQ
Med Oncol; 2012 Mar; 29(1):151-60. PubMed ID: 21259057
[TBL] [Abstract][Full Text] [Related]
3. Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas.
Sheehan GM; Kallakury BV; Sheehan CE; Fisher HA; Kaufman RP; Ross JS
Hum Pathol; 2005 Nov; 36(11):1204-9. PubMed ID: 16260274
[TBL] [Abstract][Full Text] [Related]
4. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
Ding Z; Wu CJ; Chu GC; Xiao Y; Ho D; Zhang J; Perry SR; Labrot ES; Wu X; Lis R; Hoshida Y; Hiller D; Hu B; Jiang S; Zheng H; Stegh AH; Scott KL; Signoretti S; Bardeesy N; Wang YA; Hill DE; Golub TR; Stampfer MJ; Wong WH; Loda M; Mucci L; Chin L; DePinho RA
Nature; 2011 Feb; 470(7333):269-73. PubMed ID: 21289624
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of NUCB2 mRNA expression in prostate cancer.
Zhang H; Qi C; Li L; Luo F; Xu Y
J Exp Clin Cancer Res; 2013 Aug; 32(1):56. PubMed ID: 23958433
[TBL] [Abstract][Full Text] [Related]
6. Expression of RABEX-5 and its clinical significance in prostate cancer.
Zhang H; Cheng S; Wang A; Ma H; Yao B; Qi C; Liu R; Qi S; Xu Y
J Exp Clin Cancer Res; 2014 Apr; 33(1):31. PubMed ID: 24716822
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer.
Aitchison AA; Veerakumarasivam A; Vias M; Kumar R; Hamdy FC; Neal DE; Mills IG
Prostate; 2008 May; 68(6):661-74. PubMed ID: 18213629
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
9. Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics.
March-Villalba JA; Martínez-Jabaloyas JM; Herrero MJ; Santamaria J; Aliño SF; Dasí F
PLoS One; 2012; 7(8):e43470. PubMed ID: 22916267
[TBL] [Abstract][Full Text] [Related]
10. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2000 Apr; 163(4):1183-8. PubMed ID: 10737491
[TBL] [Abstract][Full Text] [Related]
11. High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer.
Zhang H; Qi C; Wang A; Li L; Xu Y
Tumour Biol; 2014 Mar; 35(3):2025-8. PubMed ID: 24092574
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
13. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer.
Jia X; Shanmugam C; Paluri RK; Jhala NC; Behring MP; Katkoori VR; Sugandha SP; Bae S; Samuel T; Manne U
Oncotarget; 2017 Mar; 8(12):20198-20212. PubMed ID: 28423626
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
16. Expression of SOCSs in human prostate cancer and their association in prognosis.
Zhu JG; Dai QS; Han ZD; He HC; Mo RJ; Chen G; Chen YF; Wu YD; Yang SB; Jiang FN; Chen WH; Sun ZL; Zhong WD
Mol Cell Biochem; 2013 Sep; 381(1-2):51-9. PubMed ID: 23666742
[TBL] [Abstract][Full Text] [Related]
17. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases.
Martínez-Piñeiro L; Rios E; Martínez-Gomariz M; Pastor T; de Cabo M; Picazo ML; Palacios J; Perona R
Eur Urol; 2003 Apr; 43(4):342-50. PubMed ID: 12667714
[TBL] [Abstract][Full Text] [Related]
18. Detection of pelvic lymph node micrometastasis by real-time reverse transcriptase polymerase chain reaction in prostate cancer patients after hormonal therapy.
Liu DY; Xia WM; Tang Q; Wang J; Wang MW; Wang Y; Wang SJ; Ye YF; Zhou WL; Shao Y
J Cancer Res Clin Oncol; 2014 Feb; 140(2):235-41. PubMed ID: 24292502
[TBL] [Abstract][Full Text] [Related]
19. miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
Xu S; Yi XM; Zhang ZY; Ge JP; Zhou WQ
Mol Med Rep; 2016 Dec; 14(6):5025-5032. PubMed ID: 27779679
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
Singh P; Wig JD; Srinivasan R; Radotra BD
Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
